查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024709

中樞神經系統治療市場報告：按疾病、應用和地區分類，2026-2034 年

Central Nervous System Therapeutics Market Report by Disease, Application, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球中樞神經系統（CNS）治療藥物市場規模達1,570億美元。展望未來，IMARC Group預測，該市場從2026年到2034年將以5.58%的複合年成長率成長，到2034年達到2,610億美元。市場成長的主要促進因素包括：神經系統和精神疾病在人群中的盛行率不斷上升、遠距遠端醫療服務的普及以及貿易協定和夥伴關係的增加。

中樞神經系統（CNS）療法專注於治療和控制影響大腦和脊髓（構成中樞神經系統）的疾病。這些疾病涵蓋範圍廣泛，從阿茲海默症和帕金森氏症等神經退化性疾病到憂鬱症和焦慮症等精神疾病，也包括創傷性腦損傷和中風等急性疾病。治療手段多樣，包括藥物治療、外科手術、基因療法等新型治療方法。藥物包括抗憂鬱症、抗精神病藥物以及專門針對神經通路設計的藥物。在神經科學和生物技術進步的推動下，該領域的研究不斷發展。

中樞神經系統（CNS）治療產業的主要市場促進因素之一是全球神經和精神疾病盛行率的不斷上升。由於人口老化、生活方式改變和環境壓力等因素，阿茲海默症、帕金森氏症、憂鬱症和焦慮症等疾病的發生率日益成長。隨著需要遠端保健和遠距會診服務的普及也已成為市場成長的重要驅動力。新冠疫情加速了遠距遠端醫療的普及，預計這一趨勢也將持續。遠端醫療服務使患者無需前往醫療機構即可更便捷地獲得CNS疾病的醫療諮詢和處方箋。這種就醫便利性尤其有利於居住在偏遠地區的人們，從而擴大了CNS治療的患者群體。此外，監管機構越來越傾向於加速創新CNS治療藥物的核准，特別是那些能夠滿足未被滿足的醫療需求的藥物。因此，這些因素也促進了市場的發展。此外，全球化往往促進貿易協定和夥伴關係的達成，使中樞神經系統治療產品的經銷網路更加高效，並提振市場前景。

中樞神經系統（CNS）治療市場的發展趨勢與促進因素：

藥物研發的技術進步

快速的技術進步是推動中樞神經系統（CNS）治療產業發展的關鍵動力。人工智慧（AI）、機器學習和巨量資料分析等技術正與傳統的藥物發現方法相輔相成。這些技術能夠快速辨識有前景的候選藥物，加速藥物研發進程。高通量篩檢方法也日趨完善，使研究人員能夠在更短的時間內評估數千種化合物。生物資訊工具和計算模型正被擴大用於闡明分子層面的疾病通路，從而支持標靶治療的開發。這些技術進步顯著降低了新型CNS療法上市的時間和成本，為產業成長提供了強勁動力。

社會意識和醫療保健基礎設施

近年來，大眾對精神健康和神經系統疾病的認知顯著提高。這種認知的提升促使疾病得到早期診斷和治療，進而推動了對中樞神經系統（CNS）療法的需求。此外，各國政府和醫療機構日益重視精神健康，並正在建立更完善的醫療基礎設施和政策，以促進CNS療法的研發和推廣。在許多已開發國家，神經系統和精神疾病的醫療覆蓋範圍不斷擴大，使更多人群能夠獲得治療。神經科診所和復健中心等專科醫療機構的增加，進一步提升了CNS療法的市場潛力。隨著醫療基礎設施的不斷完善，高效能創新CNS療法的市場也不斷擴大。

增加研發投入

研發是中樞神經系統（CNS）治療產業的基石，而對該領域投入的增加也是市場發展的驅動力。此外，製藥公司通常與學術機構和研究組織合作，在研發活動中投入大量資源。這些夥伴關係促進了專業知識和資金的共用，從而加速了研發進程。同時，政府津貼、創業投資和官民合作關係在支持研發工作方面也扮演著日益重要的角色。這種合作環境催生了許多突破性發現，例如針對中樞神經系統疾病的標靶治療和個人化醫療方法。鑑於對高投資回報的預期以及對有效治療方法的持續需求，研發資金必將繼續成為推動中樞神經系統治療產業成長的強大動力。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球中樞神經系統治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依疾病分類

  • 神經退化性疾病
    • 主要部分
      • 阿茲海默症
      • 帕金森氏症
      • 多發性硬化症
      • 亨丁頓舞蹈症
      • 肌萎縮側索硬化症（ALS）
      • 其他
  • 神經血管疾病
  • 中樞神經系統創傷
  • 心理健康
    • 主要部分
      • 焦慮症
      • 癲癇
      • 情緒障礙
      • 精神病性障礙
      • 其他
  • 感染疾病
  • 中樞神經系統癌症
  • 其他

第7章 市場區隔：依應用領域分類

  • 醫院
  • 診所
  • 居家治療
  • 其他

第8章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第9章 SWOT 分析

第10章：價值鏈分析

第11章：波特五力分析

第12章：價格分析

第13章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Anavex Life Sciences Corp.
    • Astex Pharmaceuticals
    • Axsome Therapeutics, Inc.
    • Cerevance
    • CNS Pharmaceuticals, Inc.
    • ICON plc
    • IQVIA Inc.
    • Neuraxpharm
    • Neurocrine Biosciences, Inc.
    • Sage Therapeutics, Inc.
    • Sandoz Inc.
    • Supernus Pharmaceuticals, Inc.
    • Teva Pharma Australia Pty Ltd
Product Code: SR112026A6114

The global central nervous system (CNS) therapeutics market size reached USD 157.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 261.0 Billion by 2034, exhibiting a growth rate (CAGR) of 5.58% during 2026-2034. The growing prevalence of neurological and psychiatric disorders among the masses, the rise in telehealth and telemedicine services, and the increase in trade agreements and partnerships are among the key factors driving the market growth.

Central nervous system (CNS) therapeutics focus on the treatment and management of disorders affecting the brain and spinal cord, which make up the central nervous system. These disorders can range from neurodegenerative diseases, such as Alzheimer's and Parkinson's to psychiatric conditions such as depression and anxiety. They also cover acute conditions, including traumatic brain injuries and strokes. The treatment landscape is vast and includes various approaches, such as pharmacological interventions, surgical procedures, and newer modalities, including gene therapy. Medications can consist of antidepressants, antipsychotics, or drugs specifically designed to target neural pathways. Research in this field is continually evolving, driven by advancements in neuroscience and biotechnology.

One of the primary market drivers for the central nervous system (CNS) therapeutics industry is the rising prevalence of neurological and psychiatric disorders globally. Conditions such as Alzheimer's, Parkinson's, depression, and anxiety are becoming increasingly common due to factors, such as an aging population, lifestyle changes, and environmental stressors. With an increasing number of patients requiring CNS therapeutics, the market potential continues to expand, making it an attractive area for investment and innovation. Along with this, the rise in telehealth and telemedicine services is proving to be a significant driver in the market growth. The COVID-19 pandemic has accelerated the adoption of remote healthcare, and this trend is likely to continue. Telehealth services make it more convenient for patients to seek medical advice and obtain prescriptions for CNS disorders without the need for physical appointments. This increased accessibility is particularly beneficial for those in remote areas, broadening the patient base for CNS therapeutics. In addition, regulatory agencies are showing an increased willingness to fast-track the approval of innovative CNS therapeutic drugs, particularly those addressing unmet medical needs. Therefore, it is contributing to the market. Moreover, trade agreements and partnerships are often facilitated by globalization, providing a more streamlined distribution network for CNS therapeutic products, and creating a positive market outlook.

CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET TRENDS/DRIVERS:

Technological Advancements in Drug Discovery

The rapid advancements in technology have been a crucial driver for the CNS therapeutics industry. Traditional methods of drug discovery are being augmented by technologies such as artificial intelligence (AI), machine learning, and big data analytics. These technologies help in quicker identification of potential drug candidates, thereby speeding up the process of drug development. High-throughput screening methods have also become more sophisticated, allowing researchers to evaluate thousands of compounds in a shorter time frame. Bioinformatics tools and computational models are increasingly used for understanding disease pathways at the molecular level, aiding in the development of targeted therapies. These technological strides have significantly reduced the time and cost associated with bringing a new CNS therapeutic drug to market, providing a robust impetus for industry growth.

Public Awareness and Healthcare Infrastructure

Public awareness about mental health and neurological disorders has grown significantly in recent years. This increased awareness has led to early diagnosis and treatment, subsequently driving the demand for CNS therapeutics. Furthermore, governments and healthcare organizations are increasingly recognizing the importance of mental health, leading to better healthcare infrastructure and policies that facilitate the development and distribution of CNS drugs. In many developed countries, insurance coverage has expanded to include treatments for neurological and psychiatric disorders, making therapies more accessible to a broader population. The rise in specialized healthcare facilities, such as neurology clinics and rehabilitation centers, adds another layer of market potential for CNS therapeutics. As healthcare infrastructure continues to improve, so does the market for effective and innovative CNS treatments.

Growing Investment in Research and Development

Research and development (R&D) form the backbone of the CNS therapeutics industry, and growing investment in this area serves as a substantial market driver. Additionally, pharmaceutical companies are dedicating significant resources to R&D activities, often in collaboration with academic institutions and research organizations. Such partnerships facilitate the sharing of expertise and financial resources, thereby expediting the development process. In addition, government grants, venture capital funding, and public-private partnerships are also playing an increasing role in supporting R&D efforts. This collaborative environment has led to groundbreaking discoveries, including targeted therapies and personalized medicine approaches for treating CNS disorders. The promise of high returns on investment, coupled with the ever-present demand for effective treatments, ensures that R&D funding remains a strong driver for the growth of the CNS Therapeutics industry.

CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS INDUSTRY SEGMENTATION:

Breakup by Disease:

  • Neurodegenerative Diseases
    • Alzheimer's Disease
    • Parkinson's Disease
    • Multiple Sclerosis
    • Huntington's Disease
    • Amyotrophic Lateral Sclerosis
    • Others
  • Neurovascular Diseases
  • CNS Trauma
  • Mental Health
    • Anxiety Disorders
    • Epilepsy
    • Mood Disorders
    • Psychotic Disorders
    • Others
  • Infectious Diseases
  • CNS Cancer

Neurodegenerative Diseases represent the largest market share

The rising incidence of neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Multiple Sclerosis is a significant market driver in the central nervous system (CNS) Therapeutics industry. As the global population ages, the prevalence of these conditions is expected to escalate, increasing the demand for effective treatments. Along with this, the socioeconomic burden these diseases place on healthcare systems and families is pushing both public and private sectors to invest heavily in research and development. Technological advancements, such as biomarker identification and gene editing, are accelerating the pace of drug discovery for neurodegenerative conditions, attracting further investment. Additionally, government initiatives and regulatory support, mainly fast-track approvals and grants, provide an impetus for pharmaceutical companies to develop innovative solutions. In addition, the growing public awareness and educational campaigns around neurodegenerative diseases are also contributing to market growth by encouraging early diagnosis and treatment. All these factors collectively create a conducive environment for the expansion of the CNS Therapeutics market in the domain of neurodegenerative diseases.

Breakup by Application:

  • Hospital
  • Clinic
  • Homecare

The role of hospitals as a primary point of care for acute and chronic neurological conditions is a significant market driver in the central nervous system (CNS) therapeutics industry. Hospitals are often equipped with advanced diagnostic tools and treatment facilities, making them essential for managing complex CNS disorders. As cases of traumatic brain injuries, strokes, and emergency psychiatric episodes continue to rise, the need for specialized CNS therapeutics within hospital settings becomes increasingly crucial. The demand is further fueled by the growing number of specialized neurology departments and centers of excellence in hospitals, which require a consistent supply of CNS medications and treatments. Additionally, hospitals are key sites for clinical trials, accelerating the adoption of innovative CNS therapies.

On the contrary, the rising trend towards homecare for managing chronic and post-acute conditions is significantly influencing the Central Nervous System (CNS) therapeutics industry. As technological advancements make remote monitoring and telehealth more viable, many patients prefer receiving care in the comfort of their homes. Homecare is especially relevant for the elderly population and patients with neurodegenerative disorders who may find frequent hospital visits cumbersome. In addition, the availability of easy-to-administer medications and therapies suitable for home use is driving demand in this segment. Moreover, healthcare models are shifting towards more patient-centric approaches, further encouraging the adoption of homecare solutions. These trends not only broaden the consumer base but also open new channels for the distribution of CNS therapeutics, boosting overall market growth.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest central nervous system (CNS) therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America exhibited the largest market segment.

The central nervous system (CNS) therapeutics industry in North America is driven by the high prevalence of CNS-related disorders, including mental health conditions, neurodegenerative diseases, and acute neurological issues. According to the Centers for Disease Control and Prevention (CDC), one in five American adults experiences mental illness each year. Furthermore, an aging population in the region significantly contributes to the increased incidence of age-related neurodegenerative diseases such as Alzheimer's and Parkinson's.

In addition, technological innovation is another significant driver, with North America often leading in the development of advanced treatments, including gene therapies and neural implants. The region also benefits from strong regulatory support, with agencies providing fast-track approvals for innovative CNS drugs. Moreover, robust healthcare infrastructure, including advanced hospitals and a growing focus on telehealth services, facilitates easier access to treatments. Furthermore, substantial investment in research and development, both from public and private sectors, furthers innovation and the speed-to-market for new CNS therapies, collectively making North America a dynamic market for CNS therapeutics.

COMPETITIVE LANDSCAPE:

The key players are allocating significant resources to advance their understanding of CNS disorders, uncover novel treatment approaches, and develop new therapeutic agents. This involves conducting clinical trials, and preclinical studies, and leveraging cutting-edge technologies to identify potential drug candidates. Along with this, brands are leveraging advanced techniques, such as high-throughput screening, molecular modeling, and genetics to discover compounds with the potential to modulate CNS-related targets. These efforts aim to identify effective drug candidates that can address specific neurological conditions. In addition, the growing focus on personalized medicine within the CNS therapeutics field is positively influencing the market. Apart from this, companies are particularly focused on neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. Research efforts are aimed at unraveling the underlying mechanisms of these diseases and developing disease-modifying treatments, which act as another growth-inducing factor. Furthermore, the escalating number of collaborations with research institutions, academia, and other industry players to develop new therapeutic approaches is contributing to the market.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Anavex Life Sciences Corp.
  • Astex Pharmaceuticals
  • Axsome Therapeutics, Inc.
  • Cerevance
  • CNS Pharmaceuticals, Inc.
  • ICON plc
  • IQVIA Inc.
  • Neuraxpharm
  • Neurocrine Biosciences, Inc.
  • Sage Therapeutics, Inc
  • Sandoz Inc.
  • Supernus Pharmaceuticals, Inc.
  • Teva Pharma Australia Pty Ltd

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Central Nervous System (CNS) Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease

  • 6.1 Neurodegenerative Diseases
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Alzheimer's Disease
      • 6.1.2.2 Parkinson's Disease
      • 6.1.2.3 Multiple Sclerosis
      • 6.1.2.4 Huntington's Disease
      • 6.1.2.5 Amyotrophic Lateral Sclerosis
      • 6.1.2.6 Others
    • 6.1.3 Market Forecast
  • 6.2 Neurovascular Diseases
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 CNS Trauma
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Mental Health
    • 6.4.1 Market Trends
    • 6.4.2 Key Segments
      • 6.4.2.1 Anxiety Disorders
      • 6.4.2.2 Epilepsy
      • 6.4.2.3 Mood Disorders
      • 6.4.2.4 Psychotic Disorders
      • 6.4.2.5 Others
    • 6.4.3 Market Forecast
  • 6.5 Infectious Diseases
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 CNS Cancer
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Hospital
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Clinic
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Homecare
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Anavex Life Sciences Corp.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Astex Pharmaceuticals
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Axsome Therapeutics, Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Cerevance
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 CNS Pharmaceuticals, Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 ICON plc
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 IQVIA Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Neuraxpharm
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Neurocrine Biosciences, Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Sage Therapeutics, Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Sandoz Inc.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Supernus Pharmaceuticals, Inc.
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis
    • 13.3.13 Teva Pharma Australia Pty Ltd
      • 13.3.13.1 Company Overview
      • 13.3.13.2 Product Portfolio
      • 13.3.13.3 Financials
      • 13.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Central Nervous System Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Central Nervous System Therapeutics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Central Nervous System Therapeutics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Central Nervous System Therapeutics Market: Breakup by Disease (in %), 2025
  • Figure 5: Global: Central Nervous System Therapeutics Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Central Nervous System Therapeutics Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Central Nervous System Therapeutics (Neurodegenerative Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 8: Global: Central Nervous System Therapeutics (Neurodegenerative Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 9: Global: Central Nervous System Therapeutics (Neurovascular Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Central Nervous System Therapeutics (Neurovascular Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Central Nervous System Therapeutics (CNS Trauma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Central Nervous System Therapeutics (CNS Trauma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Central Nervous System Therapeutics (Mental Health) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Central Nervous System Therapeutics (Mental Health) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Central Nervous System Therapeutics (Infectious Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Central Nervous System Therapeutics (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Central Nervous System Therapeutics (CNS Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Central Nervous System Therapeutics (CNS Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Central Nervous System Therapeutics (Other Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Central Nervous System Therapeutics (Other Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Central Nervous System Therapeutics (Hospital) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Central Nervous System Therapeutics (Hospital) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Central Nervous System Therapeutics (Clinic) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Central Nervous System Therapeutics (Clinic) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Central Nervous System Therapeutics (Homecare) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Central Nervous System Therapeutics (Homecare) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Central Nervous System Therapeutics (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Central Nervous System Therapeutics (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: North America: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: North America: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: United States: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: United States: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Canada: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Canada: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Asia-Pacific: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Asia-Pacific: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: China: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: China: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Japan: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Japan: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: India: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: India: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: South Korea: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: South Korea: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Australia: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Australia: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Indonesia: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Indonesia: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Others: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Others: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Europe: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Europe: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Germany: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Germany: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: France: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: France: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: United Kingdom: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: United Kingdom: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Italy: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Italy: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Spain: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Spain: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Russia: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Russia: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Others: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Others: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Latin America: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Latin America: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Brazil: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Brazil: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Mexico: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Mexico: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Middle East and Africa: Central Nervous System Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Middle East and Africa: Central Nervous System Therapeutics Market: Breakup by Country (in %), 2025
  • Figure 77: Middle East and Africa: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Global: Central Nervous System Therapeutics Industry: SWOT Analysis
  • Figure 79: Global: Central Nervous System Therapeutics Industry: Value Chain Analysis
  • Figure 80: Global: Central Nervous System Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Central Nervous System Therapeutics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Central Nervous System Therapeutics Market Forecast: Breakup by Disease (in Million USD), 2026-2034
  • Table 3: Global: Central Nervous System Therapeutics Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 4: Global: Central Nervous System Therapeutics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 5: Global: Central Nervous System Therapeutics Market: Competitive Structure
  • Table 6: Global: Central Nervous System Therapeutics Market: Key Players